Last updated on April 19, 2014 at 9:20 EDT

Elsevier Launches New Open Access Journal: Translational Proteomics

May 27, 2013

GENEVA, Switzerland, May 27, 2013 /PRNewswire/ –

First articles now available online on ScienceDirect

Elsevier [http://www.elsevier.com/_recache ], a world-leading provider of scientific,
technical and medical information products and services, is pleased to announce the launch
of Translational Proteomics, an online-only, open access journal devoted to transferring
fundamental discoveries in the field of proteomics to clinical applications, accelerating
understanding and treatment of human diseases.

Jean-Charles Sanchez, Associate Professor at the University of Geneva, Head of the
Biomedical Research Proteomics Group and Director of the Proteomics Core Facility of the
Faculty of Medicine, will serve as Editor-in-Chief. The journal aims to cover all areas of
research in human proteomics using multi-disciplinary approaches to untangle complex
disease processes, such as oncology, neurology, immunology, cardiovascular diseases,
infectious diseases and any internal medical disorder. Special sections within the journal
will highlight research in areas like systems biology and integrative bioinformatics,
clinical proteomics and personalized medicine, comparative proteomics and drug
development, medical bioinformatics and biostatistics, food and health.

“With the launch of Translational Proteomics, we want to help the scientific and
medical communities overcome the challenges they face on the long path from basic research
to patient care,” said Professor Sanchez. “By focusing on connecting basic proteomics
research to ultimate clinical applications, the journal will provide a space for
publications detailing proteomics experiments, from early discovery to validation and the

“We are excited about the launch of Translational Proteomics”, added Dolors Alsina,
Executive Publisher at Elsevier. “This journal provides a unique platform for the
publication of high-quality, multi-disciplinary studies, combining research which, until
now, would have been broken into two or more specialized publications.”

For more information or to submit an article, visit


Open Access Publishing at Elsevier

Elsevier has been providing open access publishing options since 2005. Today,
researchers can choose to publish in over 1,500 hybrid journals as well as 39 full open
access journals and these numbers will continue to grow rapidly. All of Elsevier’s open
access publications have been peer reviewed, ensuring that the broader community not only
reads the latest research but that it is factual, original and of the highest quality and
ethical standards. For more information about Elsevier’s open access program, visit


About Elsevier

Elsevier is a world-leading provider of scientific, technical and medical information
products and services. The company works in partnership with the global science and health
communities to publish more than 2,000 journals, including The Lancet
[http://www.thelancet.com ] and Cell [http://www.cell.com ], and close to 20,000 book
titles, including major reference works from Mosby and Saunders. Elsevier’s online
solutions include ScienceDirect [http://www.sciencedirect.com ], Scopus
[http://www.scopus.com ], Reaxys [http://www.elsevier.com/reaxys ], ClinicalKey
[https://www.clinicalkey.com ] and Mosby’s Suite [http://www.confidenceconnected.com ],
which enhance the productivity of science and health professionals, and the SciVal suite
[http://www.scival.com ] and MEDai’s Pinpoint Review [http://www.medai.com ], which help
research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier [http://www.elsevier.com ]
employs 7,000 people worldwide. The company is part of Reed Elsevier Group plc
[http://www.reedelsevier.com/Pages/Home.aspx ], a world leading provider of professional
information solutions. The group employs more than 30,000 people, including more than
15,000 in North America. Reed Elsevier Group plc is owned equally by two parent companies,
Reed Elsevier PLC and Reed Elsevier NV. Their shares are traded on the London, Amsterdam
and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam:
REN; New York: RUK and ENL.

        Media contact
        Kristian Wilson

SOURCE Elsevier

Source: PR Newswire